QuiaPEG

Newsroom

Se nyheter från:
Page:
123456789
Apr 07, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today announced it has signed an agreement with the German company Celares GmbH to develop an optimized process suitable for large scale production of products based onQuiaPEG’sUni-Qleaver technology, including QPG-1029 according to current Good Manufacturing Practice (cGMP).

Feb 25, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today demonstrated Proof-of-Concept after positive results from a preclinical efficacy study in the QPG-1029 research project (pegylated liraglutide), for the treatment of type 2 diabetes and obesity.

Feb 11, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops versions of clinically validated or already approved drugs, today presented positive results from a preclinical study in the research project QPG-1029 (pegylated liraglutide), for the treatment of type 2 diabetes and overweight. The study evaluated the pharmacokinetic properties of QPG-1029 after intravenous and subcutaneous administration in rats.

Feb 06, 2020

QuiaPEG Pharmaceuticals Holding AB (publ) ("QuiaPEG"), which develops improved and patentable versions of clinically validated or already approved drugs using the company's unique technology platform, today announces that the company, in collaboration with a reputable global contract research company, has developed bioanalytical methods for the drug candidate QPG-1029 (PEG liraglutide) and the active drug substance liraglutide.

Page:
123456789
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message